Dynavax Technologies Corporation (NASDAQ:DVAX) has earned a consensus recommendation of “Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $28.00.
Several equities analysts have weighed in on the company. William Blair restated an “outperform” rating and set a $30.00 price target on shares of Dynavax Technologies in a report on Wednesday, August 9th. Cowen reiterated an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies in a report on Thursday, August 10th. Royal Bank Of Canada reiterated a “buy” rating and issued a $26.00 target price on shares of Dynavax Technologies in a report on Friday, September 1st. ValuEngine upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, Cantor Fitzgerald assumed coverage on Dynavax Technologies in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price for the company.
Shares of Dynavax Technologies (DVAX) traded down $0.10 on Friday, reaching $17.30. The company had a trading volume of 1,138,314 shares, compared to its average volume of 1,871,025. Dynavax Technologies has a 52 week low of $3.70 and a 52 week high of $24.45.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. GMT Capital Corp raised its position in Dynavax Technologies by 1.7% during the 3rd quarter. GMT Capital Corp now owns 3,057,437 shares of the biopharmaceutical company’s stock valued at $65,735,000 after purchasing an additional 52,300 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Dynavax Technologies by 10.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock worth $19,538,000 after acquiring an additional 199,004 shares in the last quarter. PointState Capital LP bought a new position in shares of Dynavax Technologies in the 2nd quarter worth $13,510,000. State Street Corp raised its position in shares of Dynavax Technologies by 19.7% in the 2nd quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock worth $8,099,000 after acquiring an additional 138,112 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its position in shares of Dynavax Technologies by 23.3% in the 3rd quarter. C WorldWide Group Holding A S now owns 823,825 shares of the biopharmaceutical company’s stock worth $17,712,000 after acquiring an additional 155,610 shares in the last quarter. 70.61% of the stock is owned by institutional investors and hedge funds.
About Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.